← 홈

전체 프로그램

ADC 1032 · Antibody 4684 · CGT 2713 · 다음 갱신 D-14 · 마지막 7월 31일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 3,531개
AntibodystaleRochePhase 3

Faricimab (Faricimab)

Age-Related Macular Degeneration; Diabetic Macular Edema · Non-Proliferative Diabetic Retinopathy

#Non-ProliferativeDiabeticRetinop#Antibody#Phase3#항체#면역항체+4
효능 ORR 16.9%임상시험 1상태 ACTIVE
AntibodystaleZarour, Hassane, MDPhase 2

pembrolizumab (Keytruda, Fecal Microbiota Transplant with Pembrolizumab)

Melanoma · Melanoma

#Melanoma#Antibody#Phase2#항체#면역항체+2
효능 ORR 1%임상시험 1상태 ACTIVE
ADCBiologicstaleSeagen, a wholly owned subsidia…Phase 1

Felmetatug Vedotin (Felmetatug Vedotin)

Ovarian Neoplasms; Peritoneal Neoplasms · HER2

#HER2#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 DISCONTINUED
AntibodystaleHI-Bio, A Biogen CompanyPhase 2

Felzartamab (Felzartamab)

Immunoglobulin A (IgA) Nephropathy · Immunoglobulin A (IgA) Nephropathy

#ImmunoglobulinAIgANephropathy#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
ADCBiologicstaleNational Cancer Institute (NCI)Phase 2

Fexagratinib (Fexagratinib)

Advanced Lymphoma; Advanced Malignant Solid Neoplasm · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 RECRUITING
AntibodystaleMacroGenicsPhase 2

Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off (Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off)

AML · AML

#AML#Antibody#Phase2#항체#면역항체+2
효능 ORR 0%임상시험 1상태 DISCONTINUED
AntibodystaleMacroGenicsPhase 2

Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off (Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off)

AML · AML

#AML#Antibody#Phase2#항체#면역항체+2
효능 ORR 0%임상시험 1상태 DISCONTINUED
AntibodystaleMacroGenicsPhase 2

Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off (Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off)

AML · AML

#AML#Antibody#Phase2#항체#면역항체+2
효능 ORR 0%임상시험 1상태 DISCONTINUED
AntibodystaleMacroGenicsPhase 2

Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off (Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off)

AML · AML

#AML#Antibody#Phase2#항체#면역항체+2
효능 ORR 0%임상시험 1상태 DISCONTINUED
AntibodystaleMacroGenicsPhase 2

Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose (Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose)

AML · AML

#AML#Antibody#Phase2#항체#면역항체+2
효능 ORR 0%임상시험 1상태 DISCONTINUED
AntibodystaleMacroGenicsPhase 2

Flotetuzumab 300 ng/kg/day, continuous infusion, after multi-step lead-in dose (Flotetuzumab 300 ng/kg/day, continuous infusion, after multi-step lead-in dose)

AML · AML

#AML#Antibody#Phase2#항체#면역항체+2
효능 ORR 0%임상시험 1상태 DISCONTINUED
AntibodystaleMacroGenicsPhase 2

Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose (Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose)

AML · AML

#AML#Antibody#Phase2#항체#면역항체+2
효능 ORR 0%임상시험 1상태 DISCONTINUED
AntibodystaleMacroGenicsPhase 2

Flotetuzumab 500 ng/kg/day, continuous infusion, after multi-step lead-in dose (Flotetuzumab 500 ng/kg/day, continuous infusion, after multi-step lead-in dose)

AML · AML

#AML#Antibody#Phase2#항체#면역항체+2
효능 ORR 0%임상시험 1상태 DISCONTINUED
AntibodystaleMacroGenicsPhase 2

Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multi-step lead-in dose (Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multi-step lead-in dose)

AML · AML

#AML#Antibody#Phase2#항체#면역항체+2
효능 ORR 0%임상시험 1상태 DISCONTINUED
AntibodystaleMacroGenicsPhase 2

Flotetuzumab 700 ng/kg/day, continuous infusion, after multi-step lead-in dose (Flotetuzumab 700 ng/kg/day, continuous infusion, after multi-step lead-in dose)

AML · AML

#AML#Antibody#Phase2#항체#면역항체+2
효능 ORR 0%임상시험 1상태 DISCONTINUED
ADCBiologicstaleSun Yat-Sen Memorial Hospital o…Phase 3

Fluorizoparib (Fluorizoparib)

Metastatic Breast Cancer; HRD-Positive/HER2-Negative Advanced Breast Cancer · HER2

#HER2#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+4
임상시험 1상태 RECRUITING
ADCBiologicstaleFudan UniversityPhase 2

Fluzoparib (Fluzoparib)

Breast Neoplasm; Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 RECRUITING
CGTBiologicstaleMinicirclePhase 1

Follistatin and klotho gene therapy (Follistatin and klotho gene therapy)

Healthy Adults · Healthy Adults

#HealthyAdults#CGT#Phase1#세포유전치료#CAR-T+2
임상시험 1상태 RECRUITING
AntibodystaleUniversity of Southern Californ…Phase 2

Fragmin, 5-Fluorouracil, Folinic Acid, irinotecan, bevacizumab (Fragmin, 5-Fluorouracil, Folinic Acid, irinotecan, bevacizumab)

Colorectal Cancer · FRα

#FR#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 DISCONTINUED
CGTBiologicstaleNanjing IASO Biotechnology Co.,…Phase 1

CT103A (Fully human BCMA chimeric antigen receptor autologous T cell injection, Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A))

Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE

115 / 177 페이지

← 이전다음 →